Sanara MedTech (NASDAQ:SMTI) Releases Earnings Results, Beats Expectations By $0.10 EPS

Sanara MedTech (NASDAQ:SMTI) posted its quarterly earnings data on Monday. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.10, Zacks reports. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%.

Sanara MedTech Trading Up 6.2 %

NASDAQ SMTI opened at $35.69 on Tuesday. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76. Sanara MedTech has a 12 month low of $26.00 and a 12 month high of $39.08. The company has a market capitalization of $311.97 million, a PE ratio of -36.05 and a beta of 1.37. The stock has a 50-day simple moving average of $34.43 and a 200 day simple moving average of $33.84.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SMTI shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $44.00 price target on shares of Sanara MedTech in a research note on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Sanara MedTech in a research note on Thursday, January 23rd.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.